par Richeldi, Luca;Azuma, Arata;Cottin, Vincent;Kreuter, Michael;Maher, Toby TM;Martínez, Fernando Prados;Oldham, Justin M;Valenzuela, Claudia;Clerisme-Beaty, Emmanuelle;Gordat, Maud;Wachtlin, Daniel;Liu, Yan;Schlecker, Christina;Stowasser, Susanne;Zoz, Donald F;Wijsenbeek, Marlies S;Bondue, Benjamin 
Référence The New England journal of medicine, 392, 22, page (2193-2202)
Publication Publié, 2025-06-01

Référence The New England journal of medicine, 392, 22, page (2193-2202)
Publication Publié, 2025-06-01
Article révisé par les pairs
Résumé : | Nerandomilast (BI 1015550) is an orally administered preferential inhibitor of phosphodiesterase 4B with antifibrotic and immunomodulatory effects. In a phase 2 trial involving patients with idiopathic pulmonary fibrosis, treatment with nerandomilast stabilized lung function over a period of 12 weeks. |